Carcereny E, Felip E, Reck M, et al. Updated Efficacy Results From the BIRCH Study: First-Line Atezolizumab Therapy in PD-L1–Selected Patients With Advanced NSCLC. 18th World Conference on Lung Cancer (WCLC) 2017, abstract OA 17.02.
Nivolumab plus ipilimumab versus sunitinib bij gevorderd RCC: extended follow-up CheckMate 214
okt 2019 | Uro-oncologie